Your GLP-1 Is Doing More to Your Brain Than You Think
Your brain has a system for wanting things and a separate system for enjoying things, and they are not the same circuit.
Most people assume desire and pleasure are one thing. You want something because it feels good, and if you stop wanting it, something must have changed about how good it feels. But that is not how the brain is built, and understanding the difference is the only way to understand what GLP-1 drugs are actually doing inside your head.
The wanting system runs on dopamine, specifically through a pathway that originates in an area called the ventral tegmental area, which is a small cluster of neurons deep in the brain that acts like the ignition switch for motivation. When dopamine fires from this region, you get the drive to seek, pursue, and initiate. Not the reward itself. The reaching for it.
The liking system is separate. It runs on opioid and endocannabinoid activity in different regions, and it processes the actual pleasure when you get the thing you were after.
These two systems usually run together, which is why we assume they are one. But you can suppress one without touching the other, and that is exactly what GLP-1 receptor agonists appear to be doing.
GLP-1 receptors sit inside the ventral tegmental area, and when a drug like semaglutide or retatrutide activates them, it triggers something called GABA interneurons, which are neurons whose entire job is to inhibit other neurons. These GABA neurons sit between the GLP-1 receptor signal and the dopamine neurons, and when they fire, they put the brakes on dopamine output. A 2025 study in Science Advances demonstrated exactly this circuit, showing that GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior.
The result is not that rewards stop feeling good. The result is that the brain stops generating the signal to go look for them.
A separate 2025 study in Neurobiology of Disease and Treatment looked at semaglutide's effect on reward behavior directly. Animals showed reduced reward collection, meaning they pursued rewards less, but their hedonic response when they received the reward was unchanged, and VTA dopamine activity actually increased during the moment of consumption itself. Wanting down, liking intact. The structure is exactly what the neuroscience predicts.
This is what makes the effect so invisible to the person experiencing it. If the drug made things feel worse, you would know. Your brain would register the contrast. But when it is the wanting that disappears, there is nothing unpleasant happening in the moment. You are not suffering. You are just not initiating. Not reaching. Not thinking about it.
Sex is one of the clearest examples because the drive to pursue it is so closely tied to dopamine seeking, and the baseline frequency of initiation is easy to notice in retrospect even when it is hard to notice in real time. But the same flattening applies to things like ambition, curiosity, and the pull toward hobbies or social connection, all of which depend on the same dopamine seeking circuit.
The second mechanism involves serotonin. A 2026 clinical review in Obesity Pillars proposed that GLP-1 agonists may also increase activity at something called the 5-HT2C receptor, which is a specific serotonin receptor subtype whose activation is one of the primary reasons SSRIs cause sexual side effects. The mechanism is different from the dopamine pathway, but the downstream effect on sexual desire overlaps, which means there may be two separate systems both reducing drive at the same time through completely different routes.
The authors of that review also pointed out something worth understanding about why this effect gets missed in clinical practice. Weight loss itself tends to improve sexual function and mood and body image, so a person on a GLP-1 drug may be experiencing reward suppression while simultaneously feeling better about themselves in other ways, and those competing effects can cancel each other out in self-report. The drug is doing two things pulling in opposite directions, and the net experience can feel neutral or even positive, even while the reward circuit is being dialed down.
This also explains why population-level studies can return null results. A 2024 randomized controlled trial testing dulaglutide in healthy men over four weeks found no significant change in sexual function scores. Dulaglutide has weaker central nervous system penetration than semaglutide, and four weeks may not be long enough to accumulate the effect, and the participants were healthy eugonadal men who would have the most robust baseline drive to overcome. That is not a contradiction of the mechanism. It is a demonstration of how easy the effect is to mask when you are measuring the wrong things or using the wrong drug.
The alcohol data is worth including here because it shows the same circuit operating in a completely different context. A 2025 randomized clinical trial published in JAMA Psychiatry tested once-weekly semaglutide in 48 adults with alcohol use disorder and found that it reduced alcohol consumption, craving, and the number of heavy drinking days. The drug was not targeting alcohol specifically. It was modulating the same reward-seeking pathway that drives drinking, sex drive, food pursuit, and every other motivated behavior, because there is only one dopamine wanting system and semaglutide acts on it directly.
On the question of reversibility, these drugs have a half-life of approximately one week, so within four to five weeks of stopping, receptor signaling returns to baseline and the dopamine seeking circuit comes back online. The effect is pharmacological, not structural. The brain is not changed. It is temporarily dialed down.
The insight here is not that GLP-1 drugs are dangerous or that people should stop taking them. The insight is that the brain has a system specifically for generating the desire to pursue things, and that system is not the same as the system that makes things feel good when you have them, and most of what we call motivation, libido, ambition, and curiosity runs through the wanting side, not the liking side.
Which means you can feel completely fine and still be running at a fraction of your baseline drive, and have no way of knowing it until the drug clears and the wanting comes back on.
References
- Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
- Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
- Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
- Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
- Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.